Clinical trials
HSCT clinical trials
Below are recruiting hsct clinical trials, each written for real people, not researchers. We’re tracking 152 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07126782RecruitingEarly Phase 1
Gene-edited immune cells for AML after transplant
This trial tests a type of immune cell called gamma-delta T cells in people with acute myeloid leukemia who still have minimal residual disease after a stem cell transplant. The goal is to see if these cells can clear the remaining leukemia cells safely and effectively.
BeijingAges 18 years+ - NCT07183878Recruiting
Venetoclax with BUCY conditioning for high-risk AML or MDS transplant
This trial tests whether adding venetoclax (a pill that targets cancer cells) to the standard chemotherapy regimen before a stem cell transplant improves outcomes for people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). It is for patients aged 12–60 whose cancer has specific high-risk features and who have a matched donor.
Hangzhou, ZhejiangAges 12–60 - NCT07205523Recruiting
High-altitude blood study for stem cell transplant patients
This study observes how blood and stem cell transplants work for patients with blood diseases at high altitude. It aims to learn more to help future patients.
Xining, QinghaiAges Any age - NCT05531786RecruitingPhase 1/Phase 2
Pacritinib for hard-to-treat chronic graft-versus-host disease
This early-phase study tests pacritinib, a targeted medicine, for chronic graft-versus-host disease (cGVHD) that hasn’t improved after prior treatments. If you qualify, the goal is to reduce cGVHD symptoms and improve how well you function after a stem cell transplant.
Miami, FloridaAges 18–120 - NCT07280494RecruitingPhase 1
CD7-targeted CAR-T for MRD after transplant
This trial tests a special immune cell therapy (CAR-T) that targets CD7, a protein found on T-cell leukemia and lymphoma cells. It is for people who have very small amounts of cancer remaining after a stem cell transplant.
Beijing, ChinaAges 3–80 - NCT07297173RecruitingPhase 1
Immune cell infusion plus transplant for tough leukemia
This trial tests a new two-step approach for people with hard-to-treat leukemia. First, you get chemotherapy plus an infusion of special immune cells from a partially matched donor, then a stem cell transplant. The goal is to see if this is safe and helps the leukemia go away.
BeijingAges 15 years+ - NCT07297303Recruiting
Lung health study after stem cell transplant
This study follows lung health after a stem cell transplant from a donor, to understand and manage chronic graft-versus-host disease (a condition where donor cells attack the body). It may help people who are about to have their first donor transplant.
TaipeiAges 18 years+ - NCT07362095RecruitingPhase 1/Phase 2
Luspatercept for anemia after a stem cell transplant
This study tests a drug called luspatercept to see if it can help people who have low red blood cells (anemia) after a stem cell transplant for leukemia. It may improve your energy and reduce the need for blood transfusions.
Guangzhou, GuangdongAges 18–70 - NCT01420562Recruiting
Posaconazole medicine study in transplant patients with mouth sores
This study looks at how posaconazole (an antifungal medicine) moves through the body in people who recently had an allogeneic stem cell transplant and have mouth sores (mucositis). It may help clinicians choose the safest and most effective dosing for preventing serious fungal infections.
Leuven, Vlaams-BrabantAges 18–75 - NCT01861106RecruitingPhase 2
Bone marrow transplant for people with GATA2 gene changes
This trial tests whether an allogeneic bone marrow (stem cell) transplant can improve outcomes for people with GATA2 gene changes or “MonoMAC” syndrome. It aims to rebuild a healthier immune system in patients who have serious infections and immune cell deficiencies.
Bethesda, MarylandAges 6–70 - NCT02143830RecruitingPhase 2
Stem cell transplant chemotherapy for Fanconi anemia
This Phase 2 study tests a stem cell transplant approach using adjusted chemotherapy doses for people with Fanconi anemia. It may help replace damaged bone marrow and treat blood problems like severe aplastic anemia, MDS, or leukemia.
New York, New YorkAges 3 months+ - NCT02508038RecruitingPhase 1
Test CD19+ depleted donor transplant for hard childhood cancers
This Phase 1 study tests a special type of half-matched (haploidentical) stem cell transplant plus medicines, aiming to reduce cancer relapse after transplant. It may help children and teens with certain leukemia/lymphoma or specific solid tumors who do not have a fully matched donor or whose best options are limited.
Madison, WisconsinAges 7 months–21 years - NCT03300492RecruitingPhase 1/Phase 2
Natural killer cell treatment after a half-matched stem cell transplant
This early trial studies adding special immune cells called “natural killer cells” after a half-matched stem cell transplant for AML or MDS. The goal is to see if this approach improves outcomes and safety when there is no fully matched donor available.
BaselAges 18 years+ - NCT07400328RecruitingPhase 2
Stem cell injection to prevent severe mouth sores in transplant
This trial is testing a single injection called Amimestrocel to prevent severe mouth sores in people getting a stem cell transplant. The study is for adults who are receiving high-dose conditioning with total body irradiation or melphalan, which often cause painful mouth inflammation.
Suzhu, JiangsuAges 18–65 - NCT07425782RecruitingPhase 2
Venetoclax and azacitidine as consolidation for high-risk AML
This trial tests the combination of venetoclax (a targeted pill) and azacitidine (a chemotherapy-like drug) as consolidation therapy after initial treatment in adults with high-risk acute myeloid leukemia (AML) who have achieved remission and are planning a stem cell transplant. The goal is to see if this combination helps prevent relapse before transplant.
Suzhou, JiangsuAges 18 years+ - NCT07441291RecruitingPhase 3
CAR-T vs donor immune cells for residual leukemia after transplant
This study tests whether a therapy using your own immune cells (CAR-T) works better than donor immune cells (DLI) to remove leftover leukemia cells after a stem cell transplant. The goal is to prevent the leukemia from coming back.
Beijing, ChinaAges 3–79 - NCT07442513RecruitingPhase 3
Preventing Bleeding in Stem Cell Transplant
This trial tests if a medication called etamsylate can help prevent bleeding in patients getting a stem cell transplant. If your platelet count drops very low after transplant, this drug may reduce your risk of bleeding.
Hangzhou, ZhejiangAges 18–70 - NCT07454226Recruiting
Drug combo for Ph-like acute lymphoblastic leukemia
This trial tests a combination of targeted drugs (ABL/JAK inhibitors) with chemotherapy and venetoclax for people with a type of leukemia called Ph-like ALL. It aims to see if this treatment is safe and effective.
Tianjin, Tianjin MunicipalityAges 14–60 - NCT07499284Recruiting
Haplo-Cord Stem Cell Transplant for Aplastic Anemia
This trial tests a new way of using a mix of donor stem cells (from a half-matched family member and a cord blood unit) to treat aplastic anemia, a condition where the bone marrow stops making enough blood cells. The goal is to see if this transplant approach is safe and helps rebuild healthy blood cells.
Suzhou, JiangsuAges 14 years+ - NCT07500441Recruiting
Gene test after stem cell transplant for AML
This trial uses a very sensitive blood test (digital PCR) to look for tiny amounts of leftover leukemia after a stem cell transplant, focusing on certain gene changes that are not the common fusion genes.
Beijing, Beijing MunicipalityAges Any age - NCT07500753Recruiting
Study of a conditioning regimen for older adults with hard-to-treat leukemia or MDS
This trial tests a chemotherapy combination (Clad-LABU) to prepare older patients for a stem cell transplant. It is for people aged 50 or older with relapsed or refractory AML or high-risk MDS.
Suzhou, JiangsuAges 50 years+ - NCT07511127RecruitingPhase 3
Maribavir for stubborn CMV after stem cell transplant
This trial tests whether taking maribavir for different lengths of time can help treat a stubborn CMV infection after a stem cell transplant. It is for people whose CMV hasn't improved with standard treatment.
ShanghaiAges 18–75 - NCT07569055Recruiting
Fungal Infections After Stem Cell Transplants: Long-Term Study
This study follows patients who have received a stem cell transplant from a donor to track and understand fungal infections that can occur afterward. By studying this carefully, researchers hope to better prevent and treat these serious infections in future patients.
Beijing, Beijing MunicipalityAges Any age - NCT07569653RecruitingPhase 4
CMV Prevention After Stem Cell Transplant Using Blood Tests
This trial tests whether doctors can safely stop a CMV prevention medication (letermovir) earlier by using blood tests to check your immune system's strength. CMV is a virus that can become dangerous after stem cell transplant, and this study aims to prevent it while minimizing unnecessary medicine.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new HSCT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hsct?
- Yes. Clin2 currently lists 152 recruiting hsct studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hsct trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hsct trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.